Clinical implications of cardiovascular outcome trials in type 2 diabetes.

Herz · 2019 · PMC6507479 · PMID 30805659

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

It was reassuring that the PROACTIVE trial showed that in patients with T2DM and high cardiovascular risk, pioglitazone reduced the secondary endpoint, a composite of death and nonfatal myocardial infarction or stroke (HR: 0.84; 95% CI: 0.72–0.98; p = 0.027), while the reduction of the primary endpoint, including leg amputation and revascularization, did not reach statistical significance [ 23 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.